Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOQ9H1)

• Drug Name: Tremelimumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Approved	[1]
Malignant mesothelioma	2C26.0	Phase 3	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]

• Cross-matching ID: TTD Drug ID: DMOQ9H1

Molecule-Related Drug Atlas

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[5]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[7]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[8]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[9]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[10]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[11]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
Zalifrelimab	DMNNYAE	Cervical cancer	2C77.0	Phase 1/2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Modulator	[4]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761289.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [7] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [8] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [9] Clinical pipeline report, company report or official report of MacroGenics
• [10] Clinical pipeline report, company report or official report of Xencor
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [13] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [14] Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.